Axon Enterprise (NASDAQ:AXON) Shares Up 5.9% - Still a Buy?

Axon Enterprise logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • Axon shares rose 5.9% in Thursday’s midday trading to about $318.55, while trading volume was 65% below its daily average.
  • Latest quarterly revenue grew 27.8% year over year to $908.6 million, but missed analyst expectations; EPS of $1.72 also fell short of the $1.89 consensus. Software and services revenue increased 43.2%, while federal drone-program delays and higher component costs remain headwinds.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $612.18. Thirteen analysts rate the stock Buy and four rate it Hold.
  • MarketBeat previews top five stocks to own in December.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report)'s stock price traded up 5.9% during mid-day trading on Thursday. The stock traded as high as $325.66 and last traded at $318.5470. 385,969 shares traded hands during trading, a decline of 65% from the average daily volume of 1,101,769 shares. The stock had previously closed at $300.69.

Top Axon Enterprise Stories

Investors following AXON have been watching these stories:

  • Positive Sentiment: Investors may also be encouraged by commentary on strong software and AI momentum. Software and services revenue grew 43.2% in the third quarter, supported by premium software adoption and recurring revenue. Article: Axon's Software & Services Strength
  • Positive Sentiment: Axon’s Skydio investment is now expected to be settled mostly in cash, with a smaller stock component than previously anticipated, potentially easing concerns about share dilution. Article: Axon Updates Skydio Investment Consideration to Cash
  • Negative Sentiment: Federal drone-program delays and higher component costs are still headwinds. Axon also recently missed analyst expectations for quarterly earnings and revenue, providing context for the stock’s earlier weakness.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Axon Enterprise from $755.00 to $610.00 and set an "overweight" rating for the company in a research note on Friday, November 6th. Morgan Stanley upped their target price on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. UBS Group increased their price objective on shares of Axon Enterprise from $440.00 to $600.00 and gave the stock a "neutral" rating in a report on Thursday, August 6th. Raymond James Financial set a $675.00 price target on Axon Enterprise in a report on Thursday, October 15th. Finally, The Goldman Sachs Group cut their price target on shares of Axon Enterprise from $715.00 to $675.00 and set a "buy" rating on the stock in a research report on Monday, September 21st. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $612.18.

Check Out Our Latest Report on AXON

Axon Enterprise Stock Up 3.1%

The company has a market cap of $25.25 billion, a price-to-earnings ratio of 99.47, a P/E/G ratio of 7.22 and a beta of 1.48. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.00 and a quick ratio of 2.60. The firm has a 50-day moving average price of $405.68 and a 200 day moving average price of $464.50.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.89 by ($0.17). Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. The firm had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. During the same quarter in the prior year, the business posted $1.17 EPS. The business's revenue was up 27.8% on a year-over-year basis. Sell-side analysts predict that Axon Enterprise, Inc will post 1.65 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of the company's stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president directly owned 296,974 shares in the company, valued at approximately $170,590,774.82. This represents a 5.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 1,017 shares of the company's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $480.45, for a total transaction of $488,617.65. Following the completion of the transaction, the insider directly owned 56,264 shares in the company, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,397 shares of company stock worth $21,234,034 in the last ninety days. Company insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in Axon Enterprise by 5,700.2% in the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company's stock worth $119,724,905,000 after buying an additional 209,879,882 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in Axon Enterprise by 18,050.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company's stock worth $7,400,094,000 after acquiring an additional 13,127,348 shares in the last quarter. BlackRock Inc. increased its holdings in Axon Enterprise by 4.3% in the 2nd quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company's stock worth $4,672,432,000 after acquiring an additional 345,365 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its stake in Axon Enterprise by 391,214.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company's stock worth $2,952,943,000 after acquiring an additional 6,987,098 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in Axon Enterprise by 8,432.6% during the second quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company's stock valued at $1,983,414,000 after purchasing an additional 3,496,493 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

(Get Free Report)

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Axon Enterprise Right Now?

Before you consider Axon Enterprise, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.

While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines